Early Supported Discharge (ESD) is the discharge of a stroke patient from hospital to their own home, co-ordinated by a team of therapists, nurses and a doctor. A number of ESD services have been set up across England. Do these services offer the same benefits to patients as those identified in clinical trials?
Non-invasive brain stimulation may help re-learning of movement after stroke
Cerebral small vessel disease (SVD) is usually associated with high blood pressure, and causes 20% of all strokes. It is the main cause of cognitive changes and dementia associated with stroke. Behavioural symptoms such as apathy are also common in patients with SVD.
This project will develop a special therapy area within ‘Second Life’, an existing virtual reality world on the internet. It will be protected so that only other people with aphasia and specially trained support workers can take part.
The effect of cerebrospinal fluid drainage on brain oxygenation and haemodynamics after subarachnoid haemorrhage
Torpor is a natural state of reduced energy use and body temperature. This research will look at the effect of torpor on brain activity and function, and the amount of brain damage caused by ischaemic stroke.
Stroke survivors often have very individual hopes for the future, in terms of the goals they would like to achieve. This research will develop and test a Goal setting and Action Planning (G-AP) approach to achieving personal goals through community rehabilitation.
The effect of blood pigments on brain inflammation and survival of nerve cells
Presented at the International Stroke Conference 2016, the final results from the PISTE trial (Pragmatic Ischaemic Stroke Thrombectomy Evaluation) add new evidence for the effectiveness of mechanical clot retri
Funded by the European Union (EU), a new international study called PROOF will investigate whether high-dose oxygen therapy can reduce the effects of stroke.
The Stroke Association is a member of the Stroke Alliance For Europe (SAFE), which will work on communication of information about the PROOF trial to non-clinical audiences.